AMGEN INC's ticker is AMGN and the CUSIP is 031162100. A total of 1,892 filers reported holding AMGEN INC in Q4 2018. The put-call ratio across all filers is 1.30 and the average weighting 0.7%.
About AMGEN INC
Amgen Inc. is a biotechnology company that specializes in the development of innovative medicines for the treatment of serious illnesses. The company has a strong track record of success, with a portfolio of products that includes some of the most widely used and effective drugs in the world.
One of Amgen's most important products is Enbrel, a drug used to treat rheumatoid arthritis and other autoimmune diseases. Enbrel has been a major success for the company, generating billions of dollars in revenue each year.
Amgen is also a leader in the development of cancer treatments, with a number of promising drugs in its pipeline. The company's cancer drugs are designed to target specific types of cancer cells, which can help to minimize side effects and improve patient outcomes.
In addition to its focus on drug development, Amgen is also committed to sustainability and social responsibility. The company has implemented a number of initiatives to reduce its environmental impact, and it has also established programs to support education and healthcare in underserved communities.
Overall, Amgen is a company with a strong track record of success and a commitment to innovation and social responsibility. With a portfolio of products that includes some of the most effective drugs in the world, Amgen is well positioned for continued growth and success in the years ahead.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $483,975,677 | +2.5% | 1,548,970 | -6.7% | 0.36% | +10.2% |
| Q1 2024 | $471,983,141 | -1.1% | 1,660,042 | +0.2% | 0.32% | -8.2% |
| Q4 2023 | $477,224,658 | +5.4% | 1,656,915 | -1.6% | 0.35% | -5.1% |
| Q3 2023 | $452,715,738 | +19.9% | 1,684,461 | -1.0% | 0.37% | +26.5% |
| Q2 2023 | $377,723,736 | -18.0% | 1,701,305 | -10.8% | 0.29% | -14.3% |
| Q1 2023 | $460,916,924 | -5.4% | 1,906,585 | +2.8% | 0.34% | -11.1% |
| Q4 2022 | $487,125,762 | +16.5% | 1,854,728 | -0.0% | 0.39% | +12.2% |
| Q3 2022 | $418,148,000 | -9.6% | 1,855,138 | -2.5% | 0.34% | -3.4% |
| Q2 2022 | $462,739,000 | +0.8% | 1,901,926 | +0.2% | 0.36% | +16.3% |
| Q1 2022 | $458,992,000 | +2.1% | 1,898,071 | -5.1% | 0.31% | +12.1% |
| Q4 2021 | $449,733,000 | -9.1% | 1,999,082 | -14.1% | 0.27% | -11.4% |
| Q3 2021 | $494,906,000 | -20.8% | 2,327,327 | -9.2% | 0.31% | -16.8% |
| Q2 2021 | $624,987,000 | -7.2% | 2,564,050 | -5.2% | 0.37% | -12.1% |
| Q1 2021 | $673,260,000 | +8.5% | 2,705,919 | +0.3% | 0.42% | +5.0% |
| Q4 2020 | $620,423,000 | -17.3% | 2,698,432 | -8.6% | 0.40% | -20.6% |
| Q3 2020 | $750,244,000 | +18.0% | 2,951,856 | +9.5% | 0.50% | +12.5% |
| Q2 2020 | $635,659,000 | +24.5% | 2,695,069 | +7.1% | 0.45% | +2.3% |
| Q1 2020 | $510,379,000 | -11.2% | 2,517,532 | +5.5% | 0.44% | -2.9% |
| Q4 2019 | $575,041,000 | +25.1% | 2,385,368 | +0.4% | 0.45% | +13.3% |
| Q3 2019 | $459,649,000 | +2.0% | 2,375,325 | -2.9% | 0.40% | -0.7% |
| Q2 2019 | $450,729,000 | -4.9% | 2,445,890 | -2.0% | 0.40% | -8.2% |
| Q1 2019 | $473,973,000 | -0.1% | 2,494,859 | +0.3% | 0.44% | -14.1% |
| Q4 2018 | $474,626,000 | +7.8% | 2,488,471 | +17.1% | 0.51% | +7.8% |
| Q3 2018 | $440,337,000 | +13.3% | 2,124,257 | +0.9% | 0.47% | +4.4% |
| Q2 2018 | $388,633,000 | +15.1% | 2,105,385 | +6.3% | 0.45% | +4.4% |
| Q1 2018 | $337,608,000 | -7.3% | 1,980,336 | -5.5% | 0.43% | -7.7% |
| Q4 2017 | $364,362,000 | -5.8% | 2,095,237 | +1.0% | 0.47% | -13.9% |
| Q3 2017 | $386,747,000 | +6.6% | 2,074,268 | -1.6% | 0.55% | +2.6% |
| Q2 2017 | $362,929,000 | +6.2% | 2,107,235 | +1.1% | 0.53% | +0.8% |
| Q1 2017 | $341,860,000 | +9.6% | 2,083,622 | -2.3% | 0.53% | +3.7% |
| Q4 2016 | $311,940,000 | -18.4% | 2,133,510 | -6.9% | 0.51% | -18.8% |
| Q3 2016 | $382,092,000 | +13.8% | 2,290,581 | +3.8% | 0.63% | +8.5% |
| Q2 2016 | $335,736,000 | +2.1% | 2,206,611 | +0.6% | 0.58% | +0.5% |
| Q1 2016 | $328,989,000 | -7.1% | 2,194,281 | +1.2% | 0.58% | -9.2% |
| Q4 2015 | $354,157,000 | +20.3% | 2,168,882 | +1.9% | 0.63% | +11.1% |
| Q3 2015 | $294,427,000 | -7.6% | 2,128,591 | +2.6% | 0.57% | -0.3% |
| Q2 2015 | $318,494,000 | -4.0% | 2,074,611 | -0.0% | 0.57% | -4.5% |
| Q1 2015 | $331,702,000 | +11.4% | 2,075,081 | +12.0% | 0.60% | +3.6% |
| Q4 2014 | $297,692,000 | +11.5% | 1,853,280 | -2.5% | 0.58% | +8.0% |
| Q3 2014 | $267,104,000 | +18.2% | 1,901,634 | -0.4% | 0.54% | +15.3% |
| Q2 2014 | $225,975,000 | -8.3% | 1,909,055 | -4.5% | 0.46% | -10.6% |
| Q1 2014 | $246,493,000 | +4.6% | 1,998,483 | -2.1% | 0.52% | +6.1% |
| Q4 2013 | $235,757,000 | -4.9% | 2,041,363 | -7.8% | 0.49% | -8.8% |
| Q3 2013 | $247,788,000 | +16.5% | 2,213,878 | +2.7% | 0.54% | +11.0% |
| Q2 2013 | $212,725,000 | – | 2,156,143 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| O'Keefe Stevens Advisory, Inc. | 92,877 | $22,354,000 | 9.37% |
| Oak Asset Management, LLC | 62,254 | $15,008,000 | 8.35% |
| Round Hill Asset Management | 60,589 | $14,606,000 | 7.94% |
| Smead Capital Management, Inc. | 634,139 | $152,872,000 | 6.80% |
| IAT REINSURANCE CO LTD. | 142,500 | $34,352,000 | 6.27% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 66,000 | $15,899,000 | 5.73% |
| Tekla Capital Management LLC | 617,427 | $148,843,000 | 5.63% |
| Coho Partners, Ltd. | 1,090,115 | $262,794,000 | 5.39% |
| VAN STRUM & TOWNE INC. | 34,947 | $8,425,000 | 5.19% |
| VALUEWORKS LLC | 33,814 | $8,152,000 | 5.10% |